154 related articles for article (PubMed ID: 26833957)
21. Sample size determination for comparing several survival curves with unequal allocations.
Halabi S; Singh B
Stat Med; 2004 Jun; 23(11):1793-815. PubMed ID: 15160409
[TBL] [Abstract][Full Text] [Related]
22. Tests for inter-subject and total variabilities under crossover designs.
Lee Y; Shao J; Chow SC; Wang H
J Biopharm Stat; 2002 Nov; 12(4):503-34. PubMed ID: 12477072
[TBL] [Abstract][Full Text] [Related]
23. Dynamic comparison of Kaplan-Meier proportions: monitoring a randomized clinical trial with a long-term binary endpoint.
Brittain E; Follmann D; Yang S
Biometrics; 2008 Mar; 64(1):189-97. PubMed ID: 17680830
[TBL] [Abstract][Full Text] [Related]
24. Multiple-arm superiority and non-inferiority designs with various endpoints.
Chang M
Pharm Stat; 2007; 6(1):43-52. PubMed ID: 17323311
[TBL] [Abstract][Full Text] [Related]
25. Competing time-to-event endpoints in cardiology trials: a simulation study to illustrate the importance of an adequate statistical analysis.
Rauch G; Kieser M; Ulrich S; Doherty P; Rauch B; Schneider S; Riemer T; Senges J
Eur J Prev Cardiol; 2014 Jan; 21(1):74-80. PubMed ID: 22964966
[TBL] [Abstract][Full Text] [Related]
26. Heterogeneous treatment effects in stratified clinical trials with time-to-event endpoints.
Beisel C; Benner A; Kunz C; Kopp-Schneider A
Biom J; 2017 May; 59(3):511-530. PubMed ID: 28263395
[TBL] [Abstract][Full Text] [Related]
27. A rank-based sample size method for multiple outcomes in clinical trials.
Huang P; Woolson RF; O'Brien PC
Stat Med; 2008 Jul; 27(16):3084-104. PubMed ID: 18189338
[TBL] [Abstract][Full Text] [Related]
28. Test Statistics and Confidence Intervals to Establish Noninferiority between Treatments with Ordinal Categorical Data.
Zhang F; Miyaoka E; Huang F; Tanaka Y
J Biopharm Stat; 2015; 25(5):921-38. PubMed ID: 24919157
[TBL] [Abstract][Full Text] [Related]
29. Sample size/power calculations for population pharmacodynamic experiments involving repeated-count measurements.
Ogungbenro K; Aarons L
J Biopharm Stat; 2010 Sep; 20(5):1026-42. PubMed ID: 20721789
[TBL] [Abstract][Full Text] [Related]
30. A novel test to compare two treatments based on endpoints involving both nonfatal and fatal events.
Potthoff RF; Halabi S
Pharm Stat; 2015; 14(4):273-83. PubMed ID: 25894200
[TBL] [Abstract][Full Text] [Related]
31. Design and analysis of three-arm trials with negative binomially distributed endpoints.
Mütze T; Munk A; Friede T
Stat Med; 2016 Feb; 35(4):505-21. PubMed ID: 26388314
[TBL] [Abstract][Full Text] [Related]
32. Power and sample size determination in clinical trials with multiple primary continuous correlated endpoints.
Lafaye de Micheaux P; Liquet B; Marque S; Riou J
J Biopharm Stat; 2014; 24(2):378-97. PubMed ID: 24605975
[TBL] [Abstract][Full Text] [Related]
33. Study design of single-arm phase II immunotherapy trials with long-term survivors and random delayed treatment effect.
Chu C; Liu S; Rong A
Pharm Stat; 2020 Jul; 19(4):358-369. PubMed ID: 31930622
[TBL] [Abstract][Full Text] [Related]
34. A log rank type test in observational survival studies with stratified sampling.
Bai X; Tsiatis AA
Lifetime Data Anal; 2016 Apr; 22(2):280-98. PubMed ID: 26025499
[TBL] [Abstract][Full Text] [Related]
35. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
Schmidt R; Burkhardt B; Faldum A
Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
[TBL] [Abstract][Full Text] [Related]
36. Interim analysis based on the weighted log-rank test for delayed treatment effects under staggered patient entry.
Yoshida M; Matsuyama Y
J Biopharm Stat; 2016; 26(5):842-58. PubMed ID: 26391147
[TBL] [Abstract][Full Text] [Related]
37. Sample size determination based on rank tests in clinical trials.
Wang H; Chen B; Chow SC
J Biopharm Stat; 2003 Nov; 13(4):735-51. PubMed ID: 14584719
[TBL] [Abstract][Full Text] [Related]
38. A robust approach to sample size calculation in cancer immunotherapy trials with delayed treatment effect.
Ye T; Yu M
Biometrics; 2018 Dec; 74(4):1292-1300. PubMed ID: 29992543
[TBL] [Abstract][Full Text] [Related]
39. Monitoring a three-armed clinical trial with survival endpoints: Fisher's least significant difference approach.
Chen PL; Dominik R
J Biopharm Stat; 2004 Aug; 14(3):791-801. PubMed ID: 15468765
[TBL] [Abstract][Full Text] [Related]
40. A ratio test in active control non-inferiority trials with a time-to-event endpoint.
Wang YC; Chen G; Chi GY
J Biopharm Stat; 2006; 16(2):151-64. PubMed ID: 16584064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
